DCLRE1B and adrenal cortex carcinoma: The result exhibited that DCLRE1B expression was positively associated with tumor-associated fibroblasts in ACC, KICH, KIRC, KIRP, PAAD, PCPG, THCA, and UCS using Tumor Immune Dysfunction and Exclusion (TIDE) algorithm, that strongly suggests that DCLRE1B might act as a therapeutic target for these cancers.